middle.news

Amplia Therapeutics Advances Pancreatic Cancer Trial, Secures $13M Funding Boost

7:03pm on Monday 2nd of June, 2025 AEST Pharmaceuticals
Read Story

Amplia Therapeutics Advances Pancreatic Cancer Trial, Secures $13M Funding Boost

7:03pm on Monday 2nd of June, 2025 AEST
Key Points
  • Nine confirmed partial responses in Phase 2a ACCENT trial
  • Recruitment underway for second cohort of 24 patients, with 12 enrolled
  • $13 million capital raise completed to fund ongoing trials
  • Collaboration initiated with Korean biotech Next&Bio for drug screening
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Amplia Therapeutics (ASX:ATX)
OPEN ARTICLE